Abstract
Propylene glycol (propane-1,2-diol) is the only diol widely used in dermatology. Pentane-1,5-diol is mainly used as a plasticizer in cellulose products and adhesives, in dental composites and in brake fluid compositions and as a preservative for grain. However, pentane-1,5-diol is also an effective solvent, water-binding substance, antimicrobial agent and preservative and may therefore replace several ingredients in a skin composition. The release of tri-iodothyroacetic acid (TRIAC) and percutaneous absorption of hydrocortisone and mometasone furoate with either pentane-1,5-diol or propane-1,2-diol and 2-methyl-pentane-2,4-diol (hexylene glycol), respectively, as enhancers was compared. The release of TRIAC was 21% higher when pentane-1,5-diol was used as an enhancer instead of propane-1,2-diol. The percutaneous absorption of hydrocortisone through the skin was increased 12 times with propane-1,2-diol compared to 4.4 times with pentane-1,5-diol. However, the percutaneous absorption of hydrocortisone into the skin was 50% higher with pentane-1,5-diol compared to propane-1,2-diol. There was no significant difference, between the original mometasone furoate cream, with 2-methyl-pentane-2,4-diol, and the new cream with pentane-1,5-diol in the amount of mometasone furoate that was absorbed into the skin and through the skin. However, the cosmetic properties of the new mometasone furoate cream was superior to the original mometasone furoate cream, for examples, no bad odour, more even texture, goes better into the skin and has less greasiness. Pentane-1,5-diol can be used as a technology platform, which adds a series of desirable properties to dermatological preparations and enhances product usability. This will result in improved formulations for a series of major and commonly used dermatological drugs. When used in pharmaceutical topical preparations, pentane-1,5-diol will increase the percutaneous absorption of the active substance and it is an efficient antimicrobial agent that will act as an effective preservative in topical formulations. Pentane-1,5-diol is cosmetically attractive, has low risk for skin and eye irritation compared to other diols, low toxicity risk and no bad odour.
Similar content being viewed by others
References
Bronaugh RL, Hood HL (2002) Systemic absorbtion of cutaneous material. In: Bronaugh RL, Maibach HI (eds) Topical absorbtion of dermatological products. Marcel Dekker Inc, New York, pp 163–167
Faergemann J, Fredriksson T (1980) The antimycotic activity in vitro of five diols. Sabouraudia 18:287–293
Faergemann J, Hedner T, Larsson P (2005) The in vitro activity of pentane-1,5-diol against aerobic bacteria. A new antimicrobial agent for topical usuage? Acta Dermato-Venereologica 85:203–205
Frankenfeld JW, et al (1975) Preservation of grain with aliphatic 1,3-diols and their esters. J Agric Food Chem 23:418–425
Goldsmith LA (1978) Propylene glycol. Inter J Dermatol 17:703–705
Howes D, Guy R, Hadgraft J, Heylings J, Hoeck U, Kemper F, Maibach H, Marty J-P, Merk H, Parra J, Rekkas D, Rondelli I, Schaefer H, Täuber U, Verbiese N (1996) Methods for assessing percutaneous absorption. ATLA 24:81–106
Neubert R, Bendas C, Wohlrab W, Gienau B, Furst W (1991) A multilayer membrane system for modelling drug penetration into skin. Int J Pharmaceutics 75:89–94
Rowe VK, Wolf MA (1982) Glycols; Table 50.1 Physical and chemical properties of common glycols (diols). In: Clayton GD, Clayton FE (eds) Patty’s industrial hygiene and Toxicology (3rd edn), Wiley, New York, 2c:3818–3819
Smyth HF et al (1962) Range finding toxicity data: List VI. Indus Hyg J. March–April:95–97
Yasdanparast P, Karlsson B, Oikarinen A, Risteli J, Faergemann J (2004) A thyroid hormone analog, tri-iodothyroacetic acid, restores corticosteroid down-regulated collagen synthesis. Thyroid 14:345–353
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Faergemann, J., Wahlstrand, B., Hedner, T. et al. Pentane-1,5-diol as a percutaneous absorption enhancer. Arch Dermatol Res 297, 261–265 (2005). https://doi.org/10.1007/s00403-005-0610-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00403-005-0610-8